Introduction mammary adenocarcinoma, a poorly immunogenic Cancer vaccines consisting of tumor cells genetically model, this effect was totally dependent on CD8 + T lymengineered to secrete immunostimulatory cytokines such phocytes, 6 indicating that vaccination with IFN-␣-transas GM-CSF, IL-2, IL-4 or IL-12 have been shown to duced tumor cells is able to promote the induction of induce antitumor immune responses in several murine tumor-specific CTL responses. tumor models. [1] [2] [3] Although interferon-␣ (IFN-␣) was the IFN-␣ is a cytokine secreted by antigen-presenting first cytokine used effectively in clinical trials with cancer cells, in particular by macrophages and dendritic cells, [10] [11] [12] [13] patients and is approved for the treatment of several during the early phase of viral and bacterial infections. human malignancies, its use in antitumor cytokine gene It has important immunoregulatory functions in addition therapy has not been extensively developed. 4 In preclinito its antiviral effects. IFN-␣ causes macrophage differencal models, a marked loss of tumorigenicity of tumor cell tiation, enhances the generation and increases the cytoclones stably transfected with expression plasmids contoxicity of NK cells and CD8 + cytotoxic T lymphocytes, taining IFN-␣ genes was observed in several murine and favors the generation of type 1 T helper cells. 14, 15 tumor models. [5] [6] [7] [8] [9] Rejection of IFN-␣-transduced tumor IFN-␣ has been shown to induce the expression of the ILcells resulted in the induction of a long-lasting tumor-12 receptor ␤2 subunit, which is selectively expressed by specific immunity against unmodified parental tumor human Th1 cells. 15 Interestingly, type I interferons have also been found to cause T cell receptor-independent proliferation of memory CD8 + T cells. 16 IFN-␣ also has direct oncoproteins and induces the expression of tumor supmethods. These assays confirmed production levels of bioactivate IFN-␣ corresponding to levels of immunopressor genes which contribute to its antiproliferative actions. [17] [18] [19] reactive IFN-␣ measured by ELISA. Clinical application of cytokine gene-engineered tumor cells as cancer vaccines has been problematic, in part
Preparation of retroviral producer cell lines Ecotropic retroviral supernatant was generated by transibecause of the difficulty in routinely establishing primary tumor cell lines from the vast majority of human cancers. ent transfection of DFG-mIFN␣2-neo and DFGhIFN␣2/1-neo into BOSC23 using standard calcium Most current clinical studies employ autologous tumor cells retrovirally transduced with cytokine genes, 20 which phosphate transfection in the presence of chloroquine. 29 Stable amphotropic retroviral producer cell lines were can only be obtained in a subset of the patients after several weeks of culture. Some investigators have therefore generated by infection of CRIP cells 30 with BOSC23-derived ecotropic viral supernatant. Supernatants of resorted to standardized and well-characterized allogeneic tumor cell lines retrovirally transduced with cyto-CRIP-DFG-mIFN␣2-neo and CRIP-DFG-hIFN␣2/1-neo contained bioactive mIFN␣2 and hIFN␣2/1 respectively, kine genes, which are readily available. Another possibility is to use autologous fibroblasts for gene indicating that infectious retroviral particles carrying the IFN-␣ genes had been produced by the transfected delivery, 21, 22 which can be easily obtained and cultured from virtually all individuals. Once in culture, replicating BOSC23 cells. Thus, the inherent antiviral effects of IFN-␣ did not negatively impact on the ability to generate fibroblasts can be transduced with retroviral vectors, and expanded to sufficient numbers for therapeutic purretroviral vectors and stable producer cell lines. poses. 23, 24 High levels of the cytokine of interest are expressed following selection for antibiotic resistance.
Retroviral or particle-mediated IFN-␣ gene delivery to murine tumor cells and fibroblasts Here, we demonstrate the applicability of this strategy for IFN-␣ gene delivery. Retroviral vectors were con-A series of murine tumor cell lines as well as two embryonic fibroblast lines were stably transduced with CRIPstructed on the basis of the MFG backbone. 21 Retroviral producer cell lines could be generated, which secreted DFG-mIFN␣2-neo supernatant. Cells were incubated with viral supernatant containing polybrene (8 g/ml) at infectious viral particles, in spite of anticipated problems due to the inherent antiviral and antiproliferative effects 37°C. The culture medium was replaced after 3 h and antibiotic selection applied after 48 h (0.75 mg/ml G418). of IFN-␣. Tumor cells as well as syngeneic murine fibroblasts could be retrovirally transduced, selected for antiTen to 14 days later, production of mIFN-␣2 by the selected tumor cells was measured by ELISA (Table 1 ) and biotic resistance, and quickly expanded, resulting in stable secretion of biologically active IFN-␣, suppression biological activity confirmed by viral cytopathic effect inhibition assay. Furthermore, IFN-␣-transduced cell of tumor establishment in vivo and induction of antitumor immunity.
lines displayed increased surface expression of MHC class I molecules demonstrating its intrinsic biological An alternative strategy has been the use of particlemediated gene delivery of plasmid expression vectors effects (Table 2) . Alternatively, we performed in vitro particle-mediated gene delivery to tumor cell suspensions encoding cytokine genes into freshly isolated tumor cell suspensions, resulting in transient high-level expression using pCMV-A-mIFN␣2 after optimization of transfection parameters. Production of mIFN-␣2 by 10 6 tumor which may obviate the need for viral vectors and lengthy in vitro culture periods to allow for selection of stably cells/24 h was again assessed by ELISA (Table 1 ) and biological activity confirmed. Transient particle-mediated transduced cells. [25] [26] [27] [28] This technology now utilizes a helium-driven, hand-held 'gene gun' (Accell) which protransfection resulted in significantly higher production of IFN-␣ during the first 48 h compared with stable retrovipels DNA-coated microparticles into cells or tissues. We show here that this strategy can also effectively deliver ral transduction. Because of the transient nature of particle-mediated gene delivery we followed the time-course IFN-␣ genes in vivo, capable of mediating its antitumor effects.
of cytokine production using irradiated TS/A tumor cells stably transduced with DFG-mIFN␣2-neo or transiently with pCMV-A-mIFN␣2 using the gene gun. Particle- Retroviral transduction of fibroblasts and particle- Alternatively, IFN-␣ gene delivery using particlemediated transient transfection of irradiated tumor cells was investigated. 10 6 TS/A tumor cells were transfected with either pCMV-A-mIFN␣2 or pCMV-A as control, In order to assess the induction of a long-lasting antiirradiated (100 Gy), admixed with 10 5 wild-type TS/A tumor immune response, animals that had rejected tumor cells, and injected s.c. Again, local production of TS/A-mIFN␣2 or MC38-mIFN␣2 were challenged with IFN-␣ abrogated tumor establishment ( Figure 4 ) and led 3 × 10 5 wild-type TS/A or MC38, respectively, 6 weeks to the induction of antitumor immunity as assessed by after the initial tumor challenge. All animals resisted this rechallenge and rejection of 3 × 10 5 TS/A tumor cells. rechallenge in both groups, whereas naïve animals Thus, both methods are capable of efficiently delivering developed large tumors within 14 days (data not shown).
IFN-␣ gene therapy in vivo. 
Discussion
Several groups have observed that stable transfection of mouse tumor cell lines with IFN-␣ expression plasmids Retroviral or particle-mediated IFN␣ gene delivery to human tumor cells abrogates tumorigenicity in vivo. [5] [6] [7] [8] [9] Here, we report the construction of retroviral vectors and the preparation of To assess the possible clinical application of IFN-␣ gene therapy, two established human melanoma cells were retroviral producer cell lines for IFN-␣ gene therapy of cancer and confirm their applicability and efficacy in stably transduced with CRIP-DFG-hIFN␣2/1-neo. Production of hIFN␣2/1 by 10 6 cells/24 h was verified by murine tumor models. Retroviral transduction of two poorly immunogenic mouse tumor cell lines (MC38 colon ELISA (Table 3) . IFN-␣-transduced cell lines also displayed increased surface expression of MHC class I moladenocarcinoma and TS/A mammary adenocarcinoma) prevents tumor establishment and induces tumor-specific ecules demonstrating its biological effects (Table 4) . Alternatively, in vitro particle-mediated gene delivery to immunity. Importantly, we show that syngeneic fibroblasts can efficiently be retrovirally transduced to secrete tumor cell suspensions was performed. High production of hIFN␣2/1 by 10 6 cells/24 h was shown by ELISA IFN-␣ stably. Coinjection of IFN-␣-transduced fibroblasts with wild-type TS/A suppresses tumor establishment using optimized transfection parameters (Table 3) which again resulted in increased surface expression of MHC and leads to the induction of tumor-specific immunity, indicating effective local delivery of biologically active class I molecules (Table 4 ). In two preliminary experiments, single cell suspensions prepared from freshly IFN-␣ by genetically engineered fibroblasts in vivo. We have previously successfully implemented this fibroblast excised melanoma metastases were transfected by particle bombardment; in both cases, significant, although delivery-based strategy for both IL-4 and IL-12 gene therapy of cancer 23, 24 and are currently entering phase II clinifive-fold lower amounts of hIFN␣2/1 were produced. These studies confirmed the applicability of this cal trials with the latter. A similar strategy may now be envisioned for IFN-␣ gene therapy of cancer. approach for human tumor cells in vitro.
initially led to the production of higher levels of IFN-␣ which fell to levels comparable to those produced by irradiated, retrovirally transduced tumor cells after several days. As expected, paracrine secretion of IFN-␣ following ex vivo gene gun transfection of irradiated TS/A tumor cells suppressed the establishment of coinjected wild-type TS/A tumor cells, demonstrating effective, therapeutic gene delivery in vivo.
Other investigators have vaccinated mice with irradiated melanoma cells genetically modified ex vivo to express GM-CSF with a similar particle-mediated gene transfer strategy resulting in protective antitumor immunity. 27 A clinical protocol is being proposed, where freshly isolated human melanoma cell suspensions are transfected with GM-CSF using the 'gene gun' and applied as a therapeutic vaccine for patients with metastatic melanoma. We have confirmed the feasibility of transfecting single cell suspensions prepared by digestion of freshly explanted melanoma metastases using our IFN- kine genes may be delivered directly into the tumor. The major hurdle of such in vivo gene delivery has been the comparatively low expression level of transgenes. potential safety concerns may, however, limit their applicability in humans. These new methods will have to be nation with suicide genes or genes encoding costimulatory molecules such as B7.1 will have to be investigated given the presumed synergistic action of such strategies. Using interferon-insensitive Friend leukemia cells in a As an alternative to virus-mediated gene transfer, we day 3 treatment model, perilesional injection of tumor explored the feasibility of delivering IFN-␣ genes by trancells transduced with both IFN-␣ and the suicide gene siently transfecting tumor cell suspensions using particleherpes simplex virus thymidine kinase followed by mediated gene transfer technology. Following particle administration of ganciclovir (starting on day 7) were bombardment with IFN-␣ expression plasmids incorporable to cure established tumors and induce a long-lasting ating strong CMV-IntronA-driven promoters, both immune response. 9 In preliminary experiments we murine and human engineered tumor cells transiently produced large amounts of IFN-␣. Particle bombardment observed enhanced antitumor immune responses using Tumor cells were stained with w6/32 mAb following retroviral transduction with DFG-huIFN␣2/1, gene gun transfection with pCMV-A-huIFN␣2/1 or treatment with recombinant human IFN␣2/1. Results are presented as mean fluorescence intensity.
IFN-␣ gene therapy in combination with the costimuThe cDNAs encoding mouse IFN␣2 and human IFN␣2/1 hybrid were provided by Dr P Zavodny (Schering Plough latory molecule gene B7.1.
In summary, we have demonstrated the feasibility of Research Institute). An NcoI-BamHI fragment of mIFN␣2 was generated by introducing a point mutation following IFN-␣ gene therapy for the treatment of cancer using retrovirally transduced fibroblasts as a perilesional delivthe start codon and a BamHI restriction site immediately after the stop codon using PCR techniques. An NcoIery system in vivo. We further show that particlemediated IFN-␣ gene delivery to freshly isolated tumor BamHI fragment of hIFN␣2/1 hybrid was generated by first digesting pUC18-hIFN␣2/1 with EcoRI, filling in cell suspensions can be employed as an alternative strategy, generating an effective vaccine, which obviates the with Klenow enzyme, BamHI oligonucleotide linkering, and then digesting with NcoI and BamHI. The resulting need for costly in vitro culture of patient-derived materials to be used in clinical protocols.
NcoI-BamHI fragments were inserted into a modified pGEM11. NotI-BamHI fragments were then inserted into p7077 (kindly provided by Agracetus, Middleton, WI,
Materials and methods
USA), a strong mammalian expression vector using the immediate-early gene promoter and the Intron A from Reagents CMV. NcoI-BamHI fragments of muIFN␣2 and Natural mouse IFN-␣ produced by virally infected huIFN␣2/1 were also inserted into the retroviral back-(NDV) mouse L929-cells was a kind gift of Dr P Whibone termed MFG in such a way that the translational taker-Dowling, University of Pittsburgh, Pittsburgh, PA, initiation codon ATG was fused to the ATG of the retro-USA. A sheep polyclonal anti-mouse IFN-␣ antibody was viral env gene. To obtain a retroviral construct with sela kind gift of Dr I Gresser, Institut Gustav Roussy, Paris, ectable marker an IRES-neo cassette was inserted into the France. Recombinant mouse IFN␣2 and recombinant BamHI site at the 3Ј end of muIFN␣2 and huIFN␣2/1. human IFN␣2/1 hybrid, a monoclonal anti-human IFN-
The IRES element (a cap-independent translation ␣ antibody (clone MMHA-1; Pestka Laboratories, Rutherenhancer from EMCV) allows the transcription of a single ford, NJ, USA), a sheep polyclonal anti-human IFN-␣ polycistronic message. to 2.6 m gold particles at a density of 2 g of DNA per milligram of particles. The DNA-particle preparation was Mice coated on to the inner surface of Tefzel tubing using a Female BALB/cJ or C57Bl/6 mice, 6-10 weeks old, were tube loader. The tubing was cut into 0.5 inch segments obtained from The Jackson Laboratory (Bar Harbor, ME, resulting in the delivery of 0.5 mg gold coated with 1 g USA). Animals were maintained in a specific pathogenplasmid DNA per transfection with the helium-driven free facility (Central Animal Facility, University of Accell particle bombardment device. Gold particles, tubPittsburgh).
ing, tube loader, and the Accell particle bombardment device were kindly provided by Agracetus/Geniva,
Cell lines
Middleton, WI, USA. Tumor cells were transfected in sus-TS/A is a tumor cell line established by P Nanni pension (10 6 cells per shot) in six-well plates at a pressure (University of Bologna, Bologna, Italy) from the first in of 250 p.s.i. of helium. vivo transplant of a moderately differentiated mammary adenocarcinoma spontaneously arising in a 20-month-old Retroviral transduction female Balb/cnAnCr mouse and kindly provided by G For retroviral transduction 10 6 cells in 75 cm 2 flasks were Forni (University of Torino, Turin, Italy). Mel 526 and incubated with 4 ml of viral supernatant containing Mel 624, two established human melanoma cell lines, polybrene (8 g/ml) at 37°C. The culture medium was MC38, a murine colon adenocarcinoma, MCA 205, a replaced after 3 h and antibiotic selection applied after methylcholanthrene-induced murine fibrosarcoma, and 48 h (0.75 mg/ml G418). Stable selection was completed B16, a murine melanoma, were generously provided by after 7-10 days. Dr SA Rosenberg (National Cancer Institute, Bethesda, MD, USA). The embryonic fibroblast lines TIB80 and Viral cytopathic effect inhibition assay TIB81 were purchased from ATCC (Rockville, MD, USA).
The viral cytopathic effect inhibition assay was perforAll cell lines were maintained in RPMI 1640 supmed using encephalomyocarditis virus (EMCV) on plemented with 10% heat-inactivated FCS, 2 mm l-glutamouse L929 cells. Briefly, serial half-log dilutions of IFNmine, 50 m Hepes, and 100 IU/ml penicillin and ␣ samples were performed in 96-well flat-bottomed 100 g/ml streptomycin (all reagents from GIBCO-BRL, microtiter plates and 2 × 10 4 L929 cells were added per Gaithersburg, MD, USA). BOSC23 and 293 cells were well. Following overnight incubation at 37°C, 2 × 10 3 purchased from Microbix Biosystems (Toronto, Ontario, p.f.u. of EMCV (MOI of 0.1) were added to each well. Canada) and maintained in DMEM supplemented with
The incubation was continued for an additional 48 h after 10% heat-inactivated FCS, 2 mm l-glutamine, 50 m which plates were washed and stained with crystal violet Hepes, and 100 IU/ml penicillin, and 100 g/ml streptoto observe residual viable cells. IFN activity is expressed mycin (all reagents from GIBCO-BRL).
in units/ml. The IFN activity was calibrated against the NIH reference standard for mouse IFN-␣/␤. Antibody Vector construction Maps of pCMV-A-mIFN␣2, pCMV-A-hIFN␣2/1, DFGneutralization was performed using the sheep anti-mouse IFN-␣ polyclonal antibody. mIFN␣2 and DFG-hIFN␣2/1 are presented in Figure 1 . 
